Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001641172-25-025812·Carlyle Group Inc.
Schedule 13G ownership disclosure
Phathom Pharmaceuticals Inc
Common Stock, par value $0.0001 per share · CUSIP: 71722W107
Event date: 2025-08-28
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Carlyle Group Inc.
Shares: 3,496,808.00 · Class: 4.9%
- Carlyle Holdings I GP Inc.
Shares: 3,496,808.00 · Class: 4.9%
- Carlyle Holdings I GP Sub L.L.C.
Shares: 3,496,808.00 · Class: 4.9%
- Carlyle Holdings I L.P.
Shares: 3,496,808.00 · Class: 4.9%
- CG Subsidiary Holdings L.L.C.
Shares: 3,496,808.00 · Class: 4.9%
- TC Group, L.L.C.
Shares: 3,496,808.00 · Class: 4.9%
- Carlyle Investment Management L.L.C.
Shares: 3,496,808.00 · Class: 4.9%
- Carlyle Genesis UK LLC
Shares: 3,496,808.00 · Class: 4.9%
- Abingworth LLP
Shares: 3,496,808.00 · Class: 4.9%
- Abingworth Bioventures 8 LP
Shares: 2,061,702.00 · Class: 2.9%
- Abingworth Bioventures VII LP
Shares: 1,435,106.00 · Class: 2.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001641172-25-025812
- Form type
- SCHEDULE 13G/A
- Filer
- Carlyle Group Inc.
- CIK
- CIK 1527166
- Filed
- Aug 28, 2025
- Reporting period
- Aug 28, 2025
- Description
- Schedule 13G beneficial ownership